Cargando…

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access

INTRODUCTION: Access to pimavanserin, the only Parkinson disease–related psychosis treatment approved by the FDA, is restricted by insurance requirements, a limited distribution network, and high costs. Following initiation, patients require monitoring for safety and effectiveness. The primary objec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Livezey, Sabrina, Shah, Nisha B., McCormick, Robert, DeClercq, Josh, Choi, Leena, Zuckerman, Autumn D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120983/ https://www.ncbi.nlm.nih.gov/pubmed/34026394 http://dx.doi.org/10.9740/mhc.2021.05.187

Ejemplares similares

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

Pharmacist Interventions to Improve Specialty Medication Adherence: Study Protocol for a Randomized Controlled Trial
por: Kibbons, Amanda M., et al.
Publicado: (2020)

Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy
por: Petry, Laura, et al.
Publicado: (2023)

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach
por: Shah, Nisha B., et al.
Publicado: (2019)

Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

988. Overcoming Prescriber Concerns through Successful Access and Affordability of PrEP
por: Whelchel, Kristen, et al.
Publicado: (2020)

Predicting time to medication access for hematologic malignancies: the impact of an integrated specialty pharmacy and limited distribution drug networks
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies
por: Zuckerman, Autumn, et al.
Publicado: (2023)

981. Extended Adherence and Persistence to HIV PrEP in a Multidisciplinary PrEP Clinic
por: Whelchel, Kristen, et al.
Publicado: (2020)

Development of a collaborative pharmacy practice agreement to improve efficiency and management of prescribing in a renal transplant clinic
por: Chelewski, Rachel, et al.
Publicado: (2019)

Exploring healthcare providers’ experiences with specialty medication and limited distribution networks
por: Peter, Megan E., et al.
Publicado: (2022)

Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
por: Carver, Alicia B, et al.
Publicado: (2020)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Specialty services offered by pharmacists in the community
por: Morreale, Anthony P., et al.
Publicado: (2019)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Evaluation of the impact of a clinical pharmacist on a specialty neurology clinic’s adherence to recommended laboratory test monitoring
por: Darby, Sarah, et al.
Publicado: (2021)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment
por: Ramachandran, Sharavan, et al.
Publicado: (2021)

Integrating high touch specialty pharmacy services within a neurology clinic to improve medication access and affordability
por: Newman, Brandon, et al.
Publicado: (2019)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

The protective effects of Pimavanserin against cerebral ischemia-induced brain injury
por: Li, Xiang, et al.
Publicado: (2021)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Effect of clinical pharmacist interventions on cost in an integrated health system specialty pharmacy
por: Lankford, Cory, et al.
Publicado: (2021)

Estimating the value of pharmacist interventions in a specialty pharmacy setting
por: Knowles, Grant
Publicado: (2019)

Implementation and evaluation of Parkinson disease management in an outpatient clinical pharmacist–run neurology telephone clinic
por: Stefan, Teodora Cristina, et al.
Publicado: (2018)

Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats
por: Price, Amanda E., et al.
Publicado: (2018)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q3p71o39tm6h5jdsa0c00o5ghl